Status:
COMPLETED
SAKK - a Trial to Evaluate Antitumor Efficacy of Faslodex® After Aromatase Inhibitor Failure in Advanced Breast Cancer
Lead Sponsor:
AstraZeneca
Conditions:
Breast Neoplasms
Eligibility:
FEMALE
Phase:
PHASE2
Brief Summary
The primary objective of the study is to assess the activity of fulvestrant in postmenopausal women with advanced breast cancer failing treatment with non-steroidal or steroidal aromatase inhibitors b...
Eligibility Criteria
Inclusion
- Histological/cytological confirmation of breast cancer
- progression under treatment with an aromatase inhibitor
- At least one measurable or non-measurable lesion
Exclusion
- Prior treatment for breast cancer with more than 2 different hormonal agents
- More than 1 chemotherapy for advanced disease
- Presence of life-threatening metastatic visceral disease
Key Trial Info
Start Date :
March 1 2000
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
93 Patients enrolled
Trial Details
Trial ID
NCT00272740
Start Date
March 1 2000
Last Update
February 9 2007
Active Locations (8)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Leuven, Belgium
2
Research Site
Aarau, Switzerland
3
Research Site
Bern, Switzerland
4
Research Site
Geneva, Switzerland